Furthermore, the CDK4/6 inhibitors—ribociclib, palbociclib, and abemaciclib—have been evaluated in CRC, and their therapeutic effect has been amplified in combination with other drugs [19]. The gene discussed is CDK4; the disease is colorectal carcinoma.